Search company, investor...

Verva Pharmaceuticals

vervapharma.com

Stage

Seed VC - II | Alive

Total Raised

$2.38M

Last Raised

$490K | 11 yrs ago

About Verva Pharmaceuticals

Verva Pharmaceuticals is an exciting, clinical-stage pharmaceutical company focused on the discovery and development of therapies to treat metabolic diseases (formerly Adipogen).

Headquarters Location

199 Moorabool Street Level 4

VIC 3220,

Australia

Missing: Verva Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Verva Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Verva Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Verva Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

838 items

Verva Pharmaceuticals Patents

Verva Pharmaceuticals has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/31/2013

9/27/2016

Diabetes, Kidney diseases, Vascular diseases, Transcription factors, Proteins

Grant

Application Date

5/31/2013

Grant Date

9/27/2016

Title

Related Topics

Diabetes, Kidney diseases, Vascular diseases, Transcription factors, Proteins

Status

Grant

Latest Verva Pharmaceuticals News

Verva Pharmaceuticals Ltd Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250

Jan 28, 2017

Verva Pharmaceuticals Ltd Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 03:21 EST 28 Jan 2017 | BioPortfolio Reports Home » Topics » Ertugliflozin » Latest News » Verva Pharmaceuticals Ltd Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 Summary Verva Pharmaceuticals Ltd Verva Pharma is a pharmaceutical company that develops therapeutics to treat type 2 diabetes , nonalcoholic fatty liver disease NAFLD/NASH and related complications. Its product includes VVP808. The company has completed placebocontrolled clinical proofofconcept study. Verva Pharma conducts programs to discover and characterize the biological target. It concentrates in prevention and treatment of obesity and related complications. The company has a discovery program to identify proprietary nextgeneration molecules based on the VVP808 therapeutic target. It prevents de novo fat cell formation through its technology. Verva Pharma is headquartered in Melbourne, Victoria, Australia. Verva Pharmaceuticals Ltd Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research. Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description A brief description of the company's operations. Key Employees A list of the key executives of the company. Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors A list of the key competitors of the company. Key Recent Developments A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Related Biotechnology, Pharmaceutical and Healthcare News

Verva Pharmaceuticals Frequently Asked Questions (FAQ)

  • What is Verva Pharmaceuticals's latest funding round?

    Verva Pharmaceuticals's latest funding round is Seed VC - II.

  • How much did Verva Pharmaceuticals raise?

    Verva Pharmaceuticals raised a total of $2.38M.

  • Who are the investors of Verva Pharmaceuticals?

    Investors of Verva Pharmaceuticals include Brandon Capital, GBS Venture Partners, UniSeed and Queensland BioCapital Funds.

  • Who are Verva Pharmaceuticals's competitors?

    Competitors of Verva Pharmaceuticals include Humanetics, Cornerstone Pharmaceuticals, Aegerion Pharmaceuticals, Rhythm Pharmaceuticals, Pulmatrix, CymaBay Therapeutics, Tioga Pharmaceuticals, Meditrina Pharmaceuticals, Foldrx Pharmaceuticals, Alnara Pharmaceuticals and 12 more.

Compare Verva Pharmaceuticals to Competitors

I
Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

A
Actinobac Biomed

Actinobac Biomed is a biopharmaceutical company developing therapeutics for multiple indications, including blood cancers, autoimmune/inflammatory diseases, and HIV. Its drug candidates are based upon Leukothera (LtxA), a natural protein that targets and eliminates white blood cells (WBCs) involved in the mechanism of many diseases. Products based upon Leukothera are being developed by Actinobac for the treatment of leukemia/lymphoma, dry eye, and psoriasis.

H
Hormos Medical

Hormos Medical, A Subsidiary Of Quatrx Pharmaceuticals, Focuses On Developing Therapies For Endocrine, Metabolic And Cardiovascular Diseases.

Q
QuatRx Pharmaceuticals

QuatRx Pharmaceuticals Company is focused on discovering, licensing, developing and commercializing compounds in the endocrine, metabolic and cardiovascular therapeutic areas. In addition to QRX-431, QuatRx currently has three product candidates in clinical development. QuatRx

A
Arriva Pharmaceuticals

Arriva Pharmaceuticals, Inc. offers enzyme inhibitor replacement & therapy

D
Drais Pharmaceuticals

Drais Pharmaceuticals, Inc. is dedicated to the development of therapeutic treatments that address unmet medical needs and provide significant benefits over currently available therapies.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.